Factors influencing the statistical planning, design, conduct, analysis and reporting of trials in health care: A systematic review

[1]  D. Devane,et al.  A protocol for a systematic review investigating the factors influencing the statistical planning, design, conduct, analysis and reporting of trials , 2020, HRB open research.

[2]  K. Walters,et al.  New Horizons in the use of routine data for ageing research , 2020, Age and ageing.

[3]  Diane D. Liu,et al.  Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update , 2019, Clinical trials.

[4]  T. Eliades,et al.  Methods, transparency and reporting of clinical trials in orthodontics and periodontics , 2019, Journal of orthodontics.

[5]  A. Goldkorn,et al.  Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research. , 2019, Urologic oncology.

[6]  H. Barnhart,et al.  Working With Statisticians in Clinical Research , 2018, Stroke.

[7]  Lisa V. Hampson,et al.  Adaptive designs in clinical trials: why use them, and how to run and report them , 2018, BMC Medicine.

[8]  S. Lewis,et al.  Guidelines for the Content of Statistical Analysis Plans in Clinical Trials , 2017, JAMA.

[9]  Sean M. O'Brien,et al.  How well does early‐career investigators’ cardiovascular outcomes research training align with funded outcomes research? , 2017, American heart journal.

[10]  Rory Wilson,et al.  Towards evidence-based computational statistics: lessons from clinical research on the role and design of real-data benchmark studies , 2017, BMC Medical Research Methodology.

[11]  D. DeMets,et al.  Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative , 2017, Clinical trials.

[12]  D. DeMets,et al.  Data monitoring committees: Promoting best practices to address emerging challenges , 2017, Clinical trials.

[13]  D. DeMets,et al.  Understanding the functions and operations of data monitoring committees: Survey and focus group findings , 2017, Clinical trials.

[14]  D. Berry,et al.  A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network , 2017, Clinical trials.

[15]  Hossam M. Hammady,et al.  Rayyan—a web and mobile app for systematic reviews , 2016, Systematic Reviews.

[16]  D. Berry,et al.  Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project , 2016, Trials.

[17]  A. Scrimgeour,et al.  Data sharing and the evolving role of statisticians , 2016, BMC Medical Research Methodology.

[18]  R. Califf.  Pragmatic clinical trials: Emerging challenges and new roles for statisticians , 2016, Clinical trials.

[19]  Jonathan H Seltzer,et al.  Responsibilities of Data Monitoring Committees: Consensus Recommendations , 2016, Therapeutic innovation & regulatory science.

[20]  J. Tyson,et al.  Stopping guidelines for an effectiveness trial: what should the protocol specify? , 2016, Trials.

[21]  T. Perneger,et al.  Patient enrollment and logistical problems top the list of difficulties in clinical research: a cross-sectional survey , 2016, BMC Medical Research Methodology.

[22]  P. Sandercock,et al.  Exploring the role and function of trial steering committees: results of an expert panel meeting , 2015, Trials.

[23]  S. Todd,et al.  Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials , 2015, Trials.

[24]  John Eng,et al.  Use of Spreadsheets for Research Data Collection and Preparation: A Primer. , 2015, Academic radiology.

[25]  S. Todd,et al.  Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials , 2015, Trials.

[26]  D. Berry,et al.  Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study , 2015, Clinical research and regulatory affairs.

[27]  Alexa McArthur,et al.  Innovations in the systematic review of text and opinion , 2015, International journal of evidence-based healthcare.

[28]  Hanan Khalil,et al.  Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach , 2015, International journal of evidence-based healthcare.

[29]  N. Pandis,et al.  Reporting quality of randomised controlled trials published in prosthodontic and implantology journals. , 2015, Journal of oral rehabilitation.

[30]  K. K. Snow,et al.  Processes to manage analyses and publications in a phase III multicenter randomized clinical trial , 2014, Trials.

[31]  Jim Euchner.  Design , 2014, Catalysis from A to Z.

[32]  C. Watkins,et al.  Utility values in health technology assessments: a statistician's perspective , 2014, Pharmaceutical statistics.

[33]  Julia Y. Lin,et al.  Establishing a data monitoring committee for clinical trials , 2014, Shanghai archives of psychiatry.

[34]  H. Pang,et al.  Methodological considerations in the design and implementation of clinical trials. , 2014, Seminars in oncology nursing.

[35]  R. Tibshirani,et al.  Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.

[36]  P. Archdeacon,et al.  Optimizing Expedited Safety Reporting for Drugs and Biologics Subject to an Investigational New Drug Application , 2013, Therapeutic innovation & regulatory science.

[37]  David Morgan,et al.  Multiplicity: discussion points from the Statisticians in the Pharmaceutical Industry multiplicity expert group , 2013, Pharmaceutical statistics.

[38]  B. Levin,et al.  Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop , 2012, Clinical trials.

[39]  Sandy Oliver,et al.  Narrative approaches to systematic review and synthesis of evidence for international development policy and practice , 2012 .

[40]  N. Pandis,et al.  What's in a title? An assessment of whether randomized controlled trial in a title means that it is one. , 2012, American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics.

[41]  S. Ellenberg.  Protecting Clinical Trial Participants and Protecting Data Integrity: Are We Meeting the Challenges? , 2012, PLoS medicine.

[42]  D. Dixon,et al.  Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials , 2011, Clinical trials.

[43]  T. Murphy,et al.  Gerontologic Biostatistics: The Statistical Challenges of Clinical Research with Older Study Participants , 2010, Journal of the American Geriatrics Society.

[44]  Chul Ahn,et al.  Bridging Clinical Investigators and Statisticians , 2009, Journal of Investigative Medicine.

[45]  Stephen Senn,et al.  Measurement in clinical trials: A neglected issue for statisticians? , 2009, Statistics in medicine.

[46]  K. Carroll,et al.  Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job? , 2009, Pharmaceutical statistics.

[47]  T. Fleming,et al.  Design, Conduct, and Analysis of Clinical Trials in Disease due to Methicillin‐Resistant Staphylococcus aureus , 2009, Clinical pharmacology and therapeutics.

[48]  C. Gross,et al.  Evaluating the Surgery Literature: Can Standardizing Peer-Review Today Predict Manuscript Impact Tomorrow? , 2009, Annals of surgery.

[49]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[50]  A. Nierenberg,et al.  Integrating Statistical and Clinical Research Elements in Intervention-Related Grant Applications: Summary From an NIMH Workshop , 2009, Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry.

[51]  Sergio Sismondo,et al.  Ghosts in the Machine , 2009, Social studies of science.

[52]  A. Harden,et al.  Methods for the thematic synthesis of qualitative research in systematic reviews , 2008, BMC medical research methodology.

[53]  Trevor Lewis.  Professional development of statisticians in the pharmaceutical sector: evolution over the past decade and into the future , 2008, Pharmaceutical statistics.

[54]  A. Erdemir,et al.  Ethics in a scientific approach: the importance of the biostatistician in research ethics committees , 2008, Journal of Medical Ethics.

[55]  R. Hattemer‐Apostel,et al.  Getting Better Clinical Trial Data: An Inverted Viewpoint , 2008 .

[56]  S. Hughes.  European regulatory agencies should employ full time statisticians , 2008, BMJ : British Medical Journal.

[57]  Saul Miller,et al.  Research Ethics Committee. , 2007 .

[58]  U. Harnischmacher,et al.  Consequences of Directive 2001/20/EC for investigator-initiated trials in the paediatric population—a field report , 2007, European Journal of Pediatrics.

[59]  Marvin Zelen,et al.  Biostatisticians, biostatistical science and the future , 2006, Statistics in medicine.

[60]  F. Kianifard,et al.  Teaching statistics to clinical research staff in a pharmaceutical company , 2006, Pharmaceutical statistics.

[61]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[62]  G. Preminger,et al.  Clinical research and statistical methods in the urology literature. , 2005, The Journal of urology.

[63]  J. Pignon,et al.  Clinical research infrastructures and networks in France: report on the French ECRIN workshop. , 2005, The´rapie (Paris).

[64]  T. Perneger,et al.  Medical researchers evaluate their methodological skills. , 2004, Journal of clinical epidemiology.

[65]  R. Califf,et al.  Task force 2: Investigator participation in clinical research. , 2004, Journal of the American College of Cardiology.

[66]  J. Wittes.  Playing safe and preserving integrity: making the FDA model work , 2004, Statistics in medicine.

[67]  S. Snapinn,et al.  The role of the unblinded sponsor statistician , 2004, Statistics in medicine.

[68]  D. DeMets,et al.  The independent statistician for data monitoring committees , 2004, Statistics in medicine.

[69]  S. George,et al.  Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership? , 2004, Statistics in medicine.

[70]  J. Bryant.  What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting? , 2004, Statistics in medicine.

[71]  Stuart J Pocock,et al.  A major trial needs three statisticians: why, how and who? , 2004, Statistics in medicine.

[72]  G. Campbell,et al.  Independence of the statistician who analyses unblinded data , 2004, Statistics in medicine.

[73]  D. DeMets,et al.  Issues in regulatory guidelines for data monitoring committees , 2004, Clinical trials.

[74]  Peter F Thall,et al.  Ethical issues in oncology biostatistics , 2002, Statistical methods in medical research.

[75]  S. Goodman,et al.  How statistical expertise is used in medical research. , 2002, JAMA.

[76]  A. Grieve.  Do statisticians count? A personal view , 2002 .

[77]  J Llorca,et al.  Participation of epidemiologists and/or biostatisticians and methodological quality of published controlled clinical trials , 2001, Journal of epidemiology and community health.

[78]  서정헌,et al.  반도체 공정 overview , 2001 .

[79]  Anneke Grobler,et al.  The Role of the Statistician in the Data Management Process , 2001 .

[80]  David M. L. Morgan.  Qualified Statisticians in the European Pharmaceutical Industry: Report of a European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) Working Group , 1999 .

[81]  A. Vail.  Experiences of a biostatistician on a U.K. Research Ethics Committee. , 1998, Statistics in medicine.

[82]  K. Tsang.  Evidence-based medical practice: as viewed by a clinical researcher. , 1998, Hong Kong medical journal = Xianggang yi xue za zhi.

[83]  Tosiya Sato,et al.  Expectations for an International Harmonized Guideline , 1998 .

[84]  A. Munro.  Publishing the findings of clinical research. , 1993, British medical journal.

[85]  Thomas E. Bradstreet,et al.  A Statistics Appreciation Course for Clinical Research Personnel , 1992 .

[86]  Ellenberg Jh.  Biostatistical collaboration in medical research. , 1990 .

[87]  K. James.  A model for the development, conduct, and monitoring of multicenter clinical trials in the Veterans Administration. , 1980, Controlled clinical trials.

[88]  N. Breslow,et al.  Perspectives on the statistician's role in cooperative clinical research , 1978, Cancer.

[89]  MARGARET GOWING,et al.  A Model of Development , 1973, Nature.

[90]  Rspm μgm.  Methods , 1972 .

[91]  C. Tufanaru,et al.  Chapter 7: Systematic Reviews of Etiology and Risk , 2020, JBI Manual for Evidence Synthesis.

[92]  S. Todd,et al.  Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry‐sponsored clinical trials , 2011, Pharmaceutical statistics.

[93]  Susan Todd,et al.  The potential for bias in reporting of industry‐sponsored clinical trials , 2011, Pharmaceutical statistics.

[94]  Kerry Gordon.  Who wants to be an ICH Euro billionaire? , 2008, Pharmaceutical statistics.

[95]  J. Popay,et al.  Guidance on the conduct of narrative synthesis in sytematic reviews , 2006 .

[96]  F. Rockhold.  Requiring ‘independent’ statistical analyses for industry sponsored trials? , 2006, Pharmaceutical statistics.

[97]  W Maurer,et al.  Creative and Innovative Statistics in Clinical Research and Development , 2005, Methods of Information in Medicine.

[98]  J. Hutton,et al.  Statistical review by research ethics committees , 2000 .

[99]  R. Prescott,et al.  Factors that limit the quality, number and progress of randomised controlled trials. , 1999, Health technology assessment.